Autocrine vitamin D signaling switches off pro-inflammatory programs of TH1 cells

Nature Immunology, Journal Year: 2021, Volume and Issue: 23(1), P. 62 - 74

Published: Nov. 11, 2021

Language: Английский

---

Complement activation and endothelial perturbation parallel COVID-19 severity and activity

Journal of Autoimmunity, Journal Year: 2020, Volume and Issue: 116, P. 102560 - 102560

Published: Oct. 30, 2020

Language: Английский

---

Coronavirus Disease 2019 as Cause of Viral Sepsis: A Systematic Review and Meta-Analysis*

Critical Care Medicine, Journal Year: 2021, Volume and Issue: 49(12), P. 2042 - 2057

Published: July 13, 2021

Coronavirus disease 2019 is a heterogeneous most frequently causing respiratory tract infection, which can induce failure and multiple organ dysfunction syndrome in its severe forms. The prevalence of coronavirus 2019-related sepsis still unclear; we aimed to describe this systematic review.

Language: Английский

---

Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics

Pharmacological Reviews, Journal Year: 2021, Volume and Issue: 73(2), P. 792 - 827

Published: March 9, 2021

The complement system was discovered at the end of 19th century as a heat-labile plasma component that "complemented" antibodies in killing microbes, hence name "complement." Complement is also part innate immune system, protecting host by recognition pathogen-associated molecular patterns. However, multifunctional far beyond infectious defense. It contributes to organ development, such sculpting neuron synapses, promoting tissue regeneration and repair, rapidly engaging synergizing with number processes, including hemostasis leading thromboinflammation. double-edged sword. Although it usually protects host, may cause damage when dysregulated or overactivated, systemic inflammatory reaction seen trauma sepsis severe coronavirus disease 2019 (COVID-19). Damage-associated patterns generated during ischemia-reperfusion injuries (myocardial infarction, stroke, transplant dysfunction) chronic neurologic rheumatic activate complement, thereby increasing damaging inflammation. Despite long list diseases potential for ameliorating modulation, only few rare are approved clinical treatment targeting complement. Those currently being efficiently treated include paroxysmal nocturnal hemoglobinuria, atypical hemolytic-uremic syndrome, myasthenia gravis, neuromyelitis optica spectrum disorders. Rare diseases, unfortunately, preclude robust trials. evidence pathogenetic driver many more common suggests an opportunity future therapy, which, however, requires trials; one ongoing example COVID-19 disease. current review aims discuss pathogenesis pharmacological strategies treat these complement-targeted therapies.

Significance Statement

host's defense friend from invading pathogens, maintaining homeostasis. sword, since overactivated becomes enemy, damage, failure, and, worst case, death. A acute candidates avoid complement-dependent ranging well established possible large patient groups like pandemic 2019.

Language: Английский

---

Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules

Nature Immunology, Journal Year: 2022, Volume and Issue: 23(2), P. 275 - 286

Published: Jan. 31, 2022

Language: Английский

---